MAPT and Alzheimer disease: Zhang et al.[19] recently reported development of an 18 F labeled compound ([18 F] T807) which demonstrated high affinity and selectivity for tau in competitive assays designed to assess tau binding in post-mortem human brain slices derived from individuals with AD.